-+ 0.00%
-+ 0.00%
-+ 0.00%
Vanda Pharmaceuticals Q3 2026 net loss narrows 64% from Q2 to $22.6 million; Q3 2026 total revenues rise 24% year over year to $69.8 million
Share
Listen to the news
Vanda Pharmaceuticals Q3 2026 net loss narrows 64% from Q2 to $22.6 million; Q3 2026 total revenues rise 24% year over year to $69.8 million
  • Vanda Pharmaceuticals’ Q3 2026 net loss narrowed 64% from Q2 2026 to $22.6 million.
  • Revenue rose 24% year-over-year to $69.8 million, while operating expenses fell 18% from Q2 2026 to $93.3 million.
  • BYSANTI’s commercial launch is expected in Q4 2026; Quimilza’s FDA review has a December 12, 2026 target action date.
  • Full-year 2026 revenue is expected to exceed $240 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610281601PR_NEWS_USPR_____PH83656) on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending